2011 Board

Patty Kiang, President
Dr. Patty Kiang has a broad experience in Biotech and Pharmaceutical industry with leadership, beginning from a bench chemist, quality control to product development. She has been a technical director, CMC leader and Sales/Marketing director in the pharmaceutical/biotech industry working for many companies including Genentech, Schering Plough and West Pharmaceutical. Under her leadership, she and her team have successfully filed and received FDA approval of several products (liquid Interferon, PEG-Interferon, Growth Hormone and many small molecule drug products).
Currently she is the President of Kiang Consultant Services and provides various business needs. Prior to consulting, she was the head of Business Development and Account Director for Catalent Pharma Solutions. She covers most of the Sales and Marketing of Analytical and Biotech Services to Biotech and Pharmaceutical companies in the west coast of USA all the way up to British Columbia, Canada plus Asia Pacific and Australia territory.

Dr. Julie Yang, Public Relations
Julie has a Ph. D, and is a Registered Patent Agent. Currently, she is a Senior Director of IP at Limerick BioPharma, Inc., taking care of IP, contracts and related matters for the company. Prior to Limerick, she was responsible for the IP portfolio of Genelabs Technologies, Inc. Before moving to the Bay Area, she worked in biotech R&D and management around Boston area. She would like to contribute to the activities and promotion of the CBA, as well as to the information exchange between CBA members and other professional organizations.

Li-Fen Lee, Conference Chair
Dr. Li-Fen Lee is currently Sr. Principal Scientist at Rinat-Pfizer, South San Francisco, A Project leader for preclinical studies in inflammatory diseases and cancer. She is one of the contributing authors for Rinat-Pfizer's patent portfolio. Prior to joining Rinet-Pfizer, she was an instructor at Stanford University and directed research on Hematopoietic stem cell transplantation in animal model of Type I Diabetes and Multiple Sclerosis. Dr. Lee did her postdoctoral fellowships at Stanford University, UC Davis, and Univ. of NC, Chapel Hill in various cancer and diabetes research. She received her PhD in Biology from UNC Chapel Hill, and MS in Microbiology and Immunology from National Yang-Ming University, Taipei, Taiwan. She has received numerous honors and awards from different organizations and she has many publications published in major journals.

Cindy Liu, Secretary
Ms. Liu has over 10 years of working experience in academic, biotech and pharmaceutical. She has worked in research, development, and quality. Her past experience includes research work at University of Maryland and UCSF, assay development for Bionetics, and technical management as well quality assurance for SynPep. Currently she is working in product quality control at Solstice Neurosciences. Cindy received her Master degree of Molecular Biology from University of Maryland. Cindy has been a CBA member for more than 10 years and has volunteered herself in many CBA events in past years. For leisure, she likes photography, gardening and enjoys spending time with her two sons.

Katherine Wang, Treasurer
Katherine Wang got her B.S. degree in Optics from Shandong University, and Ph.D. in Physics from Syracuse University (Syracuse, NY). She worked as research scientist in Neurodegenerative Diseases Center of University of Virginia. She has years of Hands-on experiences in optical engineering, DNA sequencing, protein purification, drug-protein interactions and cell culture. Professionally trained as physicist, later discovered that her real interest is in clinical data analysis.
Currently, she is a clinical SAS programmer at Gilead Sciences, doing data analysis in clinical trials: Phase 1 to 4. Prior to Gilead, she worked as certified advanced SAS programmer in Clinovo. Clinovo is a Bio-IT company focusing on meeting the needs of data management of Bio-Pharmaceutical and medical device industries. Katherine has been a volunteer of CBA in past two year as treasurer. Her diligent work and enthusiasm have been well recognized. She grew up in Wuhan, China and enjoys reading, writing, walking in nature and Scottish Country Dancing.

Cesar Ho, Publication
Mr. Cesar Ho is a senior staff at DG Architects, a medium-sized firm based in Mountain View that specializes in the design of high-tech projects for clients based in the Silicone Valley and beyond. It is in this capacity that he comes in contact with many of the leading biotech and pharmaceutical companies that have a presence in the Bay Area. A short list includes Merck, Roche, Abbott Labs, Genentech, Revance, Pacific Biosciences, and Children's Hospital Oakland Research Institute. Prior to joining DGA, Cesar has worked for some of the largest architectural firms in the country such as SOM, HOK and Gensler. Besides the US, he has lived and worked in Hong Kong, Thailand, and Singapore, among other places. Cesar received his M. Arch degree from the University of Illinois in Urbana-Champaign, and his Bachelor degree from the University of Pennsylvania.

Frank Lin, Web Developer & Public Relation
Mr. Frank Lin is the Regional Sales Marketing Director at Specialdeals.com, a VC funded startup a deal-of-the-day website that features discounted gift certificates usable at local or national companies. Frank Lin is the Regional Marketing Director in US and General Manager in Asia Pacific at Matchbin, Inc, a Web 2.0 Content Management System (CMS) provider for newspaper/radio station/magazine industry. Prior to that, Mr. Lin was a Sales Operation / Marketing Specialist at VeriSilicon, a Fabless Semiconductor company.
Mr. Lin grew up with family business in Biotech/Medical Device and is interested in building business relationships in Biotech industry. Mr. Lin received his B.A. degree in Electrical and Computer Engineering from Purdue University and an MBA from Santa Clara University.

Andrew Teng, Marketing/Alliance Management
Currently a Managing Director at Ecos Lab Co. Mr. Teng has more than 16 years of general management experience in the fields of semiconductor and Bio Science. His broad background includes P&L, operational, BD, product development, marketing, IP protection and M&A. Prior to joining Ecos Lab, Mr. Teng held a senior positions with Encepho Pharmaceutical as V.P. of Business Development. Mr. Teng has extensive international experience having had direct responsibility for business development and strategic planning in Greater China. Mr. Teng has a B.S. degree from San Jose State University

Cheng-Chi Chao, Program
Dr. Chao holds Ph.D. degree in Immunology from University of Iowa and B.S. from National Chung-Hsiung University, Taiwan. Dr. Chao was a postdoctoral fellow in the Department of Microbiology and Immunology at Stanford University. After finishing postdoctoral training at Stanford, he joined Systemix (a Novartis company) as a scientist to study transplantation and cancer immunology for novel drug targets. Thereafter, he joined Nuvelo (formerly Hyseq) as a senior scientist/project leader. His works involved in selection and validation of drug lead and being responsible for animal modeling and in vivo studies. Prior to joining DNAX, he returned to Taiwan as a visiting scientist at Genome Research Center, Academia Sinica in Taipei.
He is currently a senior scientist in Schering-Plough Biopharma (formerly DNAX research institute). He is involved in the pre-clinical drug validation and implementation of animal models for human diseases. Dr. Chao has been CBA Vice President in 2007 and 2008.

Jeng Her, Program
Dr. Jeng Her started his career as a co-founder of KaloBios Pharmaceuticals, Inc., a therapeutic antibody company which has raised over $76 mil in private rounds since its inception in 2001. The protein-protein interaction selection system, the antibody Humaneering™ and the antibody affinity maturation technologies that he co-invented with Dr. Robert Balint and other scientists there have led to filing of 18 patents in US and worldwide, and eventually become the technology cornerstones for a pipeline of several antibody drugs in various stages of clinical development for inflammatory, oncology and infectious diseases. In addition to KaloBios, he is also a founding scientist and VP of R&D at Multispan, Inc., a company dedicated to developing GPCR-related specialty reagents and providing superior services for cell-based drug profiling, based on a mammalian expression system developed by him and others.

Ta-Kai Li, Program
Dr. Li received his Ph.D. Degree in Biochemistry from University of Maryland School of Medicine and B.S. Degree in Chemistry from Tamkang University, Taiwan. His postdoctoral training was to study T cell activation pathways at Dana-Farber Cancer Institute/Harvard Medical School and National Institutes of Health. After completing postdoctoral training, Dr. Li came to Bay Area to work as a research scientist in biopharmaceutical industry, and he gained extensive experience with small molecules in drug screening, assay development, and mechanistic study. Later, Dr. Li joined Stanford University for research on human hepatitis C virus (HCV) and avian influenza (H5N1) virus. In Stanford, Dr. Li generated a panel of human monoclonal antibodies exhibiting potent neutralization of HCV and H5N1 virus infectivity.
Dr. Li’s has more than fifteen year experience in research encompassed mall molecules and antibodies. In addition, he has strong interest in clinical development of drugs, biologics, and medical devices. Dr. Li holds Certificate in Clinical Trials Design and Management from the University of California Extension, Santa Cruz. Currently, Dr. Li, a drug safety professional, is Pharmacovigilance Scientist at Janssen Alzheimer Immunotherapy Research & Development, LLC. He focuses on pharmacovigilance science and risk management.

Peiwen Yu, Program
Peiwen received her Ph.D. in Immunology/Pathobiological Sciences from the School of Veterinary Medicine University of Wisconsin-Madison, and her BS and MS in Animal Science form National Taiwan University. She has over 20 years of experience in biopharmaceutical industry and research, focusing on drug discovery and development in oncology and inflammation/immunology. She is currently Senior Director of Molecular and Cellular Pharmacology with Exelixis, Inc. since 2001; manages a team of 25 staffs; established and leads the Cell facility, Core assay team and Blood biomarker core; coordinates clinical and discovery research programs. Prior to joining Exelixis, she worked at Rigel, Inc. for 4 years after her post-doctoral research fellowships at Hoffman-La Roche. She is a member of ASH, AAI, and CABS. Recently she jointed the board of TFGHAA-NC and leads the publication group.

Nicki Chin, Program
Ms. Chin is currently Application support scientist at Affymetrix, Santa Clara, CA. She provides technical support and new product development and conducts internal training to field support and service teams. Prior to Affymetrix, she was Sr. Associate, Lead Discovery at Amgen, South San Francisco, CA, responsible for discovery and validation of new target genes using gene expression microarray, QPCR, and SiRNA library screening and involved in new technologies evaluation for R &D and external collaboration, such as the collaboration with Oncology Department by providing training across Amgen, established SOP for high–throughput QPCR analysis etc.
Prior to joining Amgen, she worked for Stanford University as LSRA II at Stanford Functional Genomic facility, Microarray Core Facility. Nicki led the technical support and training and quality control activities; she also worked at Genetics Department, supported cDNA microarray production, supervised cell culture production etc. Prior to joining Stanford University, she worked for Genzyme Transgenic Lab, Rockville, MD as Research Associate, responsible for monoclonal antibody development and performed various phases of clinical vaccine production, and Quality Control. Nicki received her master degree from Cornell University, school of Veterinary Medicine, Ithaca, NY and her BS degree from Taipei Medical University, Dept of Health and Nutrition.

Patrick Yang, Program
Dr. Patrick Yang currently is working at Portola Pharmaceuticals, Inc. He has been working in bay area for nine years as scientist/staff scientist in various pharmaceutical companies, Millennium Pharmaceuticals, Inc., Nektar Therapeutics Inc. and Sunesis Pharmaceuticals Inc. Dr. Yang graduated from Nanjing University, and obtained his Ph. D. in pharmaceutical sciences from University of the Pacific, USA. He also has several years’ working experience in analytical field and management in China.
Dr. Yang’s research interests include analytical development, method transfer/validation, pre-formulation/formulation, and controlled release of drug. Additionally, he has previously served on CBA board from 2003 to 2005.

Sun-Hoffman Lin, Consultant
Dr. Sun-Hoffman currently is a consultant and also serves as Biotechnology Industry Organization’s (BIO) Chief Advisor for Asia. She was President of Chinese Biopharmaceutical Association (CBA) from 2008-2009. She successfully lead the organization to hold its annual conference in Shanghai, in May 2008.
Dr. Sun-Hoffman is also active in the area of green technology. In March 2009, she was appointed as Vice President of Public Relation and General Secretary of the Board at US-China Green Energy Council founded in Bay Area in 2008.
Dr. Sun-Hoffman has been in the patent field for more than 10 years and was a USPTO patent examiner. She has more than 10 year of biotech research experience including working at NIH. In addition, she also drafted and negotiated various licenses for biotech companies.
Dr. Sun –Hoffman served as a Sr. Patent Attorney at Life Technologies Corporation formerly Applied Biosystmes, one of the biggest biotech company in US. Previously, she was a managing patent attorney at Celera Genomics, the first company sequenced human genome.
Dr. Sun-Hoffman is admitted to the Maryland Bar and registered to practice before the U.S. Patent and Trademark Office.

Ying Wang, Consultant
TBD

2010 Board Members